Literature DB >> 9760073

Significant change in tests of neurological impairment in patients with brain tumours.

Z Clyde1, S J Chataway, D Signorini, A Gregor, R Grant.   

Abstract

There is a need for valid objective tests of neurological improvement or deterioration to more accurately define response or progression in phase II studies of malignant glioma. The Edinburgh Functional Impairment Tests (EFIT) incorporate objective measures of upper and lower limb function, memory and a rating scale for dysphasia. We examined the intra-observer repeatability of the (EFIT) 24 hours apart in 55 patients with brain tumors and stable neurological disease and the inter-rater repeatability in 33 patients in the perioperative period (54 dual assessments). Intra-observer studies of the four subtests, failed to demonstrate any learning effect and showed close agreement. Inter-rater studies were affected by a treatment effect (steroids) and identified slight inter-rater bias for the ten meter walk. Altman-Bland plots showed that the level of agreement was less good in patients with more severe impairment. Correction for the severity of handicap was possible using a simple formulae: (timed tests: [rater 1 - rater 2]/[rater 1 + rater 2], Williams Delayed Recall Test [WDRT] (rater 1 - 2/81). Using this correction, all intra- and inter-rater variance of patients tested within 12 hours were < 0.2. A change of > or = 0.2 for the timed tests and WDRT, and a change in dysphasia score of > or = 2, represent a significant change in impairment using the EFIT. The EFIT should be a useful addition in phase II studies where objectively recording response or time to progression is important.

Entities:  

Mesh:

Year:  1998        PMID: 9760073     DOI: 10.1023/a:1005950003774

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  14 in total

1.  Cerebral vascular accidents in patients over the age of 60. II. Prognosis.

Authors:  J RANKIN
Journal:  Scott Med J       Date:  1957-05       Impact factor: 0.729

2.  Statistical methods for assessing observer variability in clinical measures.

Authors:  P Brennan; A Silman
Journal:  BMJ       Date:  1992-06-06

3.  Response criteria for phase II studies of supratentorial malignant glioma.

Authors:  D R Macdonald; T L Cascino; S C Schold; J G Cairncross
Journal:  J Clin Oncol       Date:  1990-07       Impact factor: 44.544

4.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

5.  Arm function after stroke: measurement and recovery over the first three months.

Authors:  A Heller; D T Wade; V A Wood; A Sunderland; R L Hewer; E Ward
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-06       Impact factor: 10.154

6.  Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.

Authors:  M D Walker; E Alexander; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; H A Norrell; G Owens; J Ransohoff; C B Wilson; E A Gehan; T A Strike
Journal:  J Neurosurg       Date:  1978-09       Impact factor: 5.115

7.  Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests.

Authors:  D E Goodkin; D Hertsgaard; J Seminary
Journal:  Arch Phys Med Rehabil       Date:  1988-10       Impact factor: 3.966

8.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

9.  Recording neurological impairment in clinical trials of glioma.

Authors:  R Grant; J Slattery; A Gregor; I R Whittle
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

10.  Phase II study of tauromustine in malignant glioma.

Authors:  A Gregor; R Rampling; M Aapro; P Malmström; I R Whittle; R Rye; M Stewart; R Sellar; B Demierre; J W Ironside
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

View more
  8 in total

1.  Overview: Brain tumour diagnosis and management/Royal College of Physicians guidelines.

Authors:  R Grant
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

2.  Neurocognitive and sociodemographic functioning of glioblastoma long-term survivors.

Authors:  Birgit Flechl; Michael Ackerl; Cornelia Sax; Karin Dieckmann; Richard Crevenna; Alexander Gaiger; Georg Widhalm; Matthias Preusser; Christine Marosi
Journal:  J Neurooncol       Date:  2012-05-29       Impact factor: 4.130

Review 3.  Depression and glioblastoma, complicated concomitant diseases: a systemic review of published literature.

Authors:  Luke Mugge; Tarek R Mansour; Megan Crippen; Yasaman Alam; Jason Schroeder
Journal:  Neurosurg Rev       Date:  2018-08-09       Impact factor: 3.042

4.  Pitfalls in the assessment of disability in individuals with low-grade gliomas.

Authors:  Anneli Påhlson; Lena Ek; Gerd Ahlström; Anja Smits
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

5.  Imaging response to chemotherapy with RMP-7 and carboplatin in malignant glioma: size matters but speed does not.

Authors:  Robert Grant; Mark Walker; Donald Hadley; Tina Barton; Chester Osborn
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

6.  A prospective open-label study of sirolimus for the treatment of anti-Hu associated paraneoplastic neurological syndromes.

Authors:  Adriaan H de Jongste; Teun van Gelder; Jacoline E Bromberg; Marieke T de Graaf; Jan W Gratama; Marco W Schreurs; Herbert Hooijkaas; Peter A Sillevis Smitt
Journal:  Neuro Oncol       Date:  2014-07-03       Impact factor: 12.300

7.  Practical problems with the collection and interpretation of serial quality of life assessments in patients with malignant glioma.

Authors:  M Walker; J Brown; K Brown; A Gregor; I R Whittle; R Grant
Journal:  J Neurooncol       Date:  2003-06       Impact factor: 4.130

8.  Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes.

Authors:  Anna E M Bastiaansen; Adriaan H C de Jongste; Marienke A A M de Bruijn; Yvette S Crijnen; Marco W J Schreurs; Marcel M Verbeek; Daphne W Dumoulin; Walter Taal; Maarten J Titulaer; Peter A E Sillevis Smitt
Journal:  Neurooncol Adv       Date:  2021-09-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.